Biotecnología Médica y Farmacéutica, Centro de Investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, Guadalajara, Jalisco, Mexico. fl
Int J Tuberc Lung Dis. 2012 Jun;16(6):774-6. doi: 10.5588/ijtld.11.0735. Epub 2012 Apr 9.
Despite the availability of a Mycobacterium bovis bacille Calmette Guérin (BCG) vaccine, tuberculosis (TB) remains a global public health problem. In this study, we introduced the c-di-GMP phosphodiesterase gene Rv1357c, implicated in regulating mycobacterial replication within macrophages, into BCG Pasteur, and tested the resulting strain for its capacity to serve as a vaccine against TB in a murine model. Modified BCG was more phagocytosed than its parental strain, but halted bacterial replication, and protected against M. tuberculosis challenge similarly to unmodified BCG.
尽管有牛分枝杆菌卡介苗(BCG)疫苗可用,但结核病(TB)仍然是一个全球性的公共卫生问题。在这项研究中,我们将涉及调节分枝杆菌在巨噬细胞内复制的 c-di-GMP 磷酸二酯酶基因 Rv1357c 导入到 BCG 卡介苗中,并在小鼠模型中测试了该菌株作为 TB 疫苗的能力。与亲本菌株相比,改良后的 BCG 被吞噬的程度更高,但它阻止了细菌的复制,并能像未改良的 BCG 一样有效地保护机体免受结核分枝杆菌的攻击。